drugset
drugset / Trial / NCT06223880

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

NCT06223880 ↗

Phase 4 Recruiting 350 enrolled Axsome Therapeutics, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a randomized, double-blind, active-controlled, multi-center study to evaluate the efficacy of AXS-05, compared to bupropion, in preventing the relapse of depressive symptoms in subjects with major depressive disorder (MDD) who have responded to treatment with AXS-05.

Timeline

Start
2023-12-27
Primary completion
2026-03
Completion
2026-03

Drugs

EvaluationDrugModalityDoseRoute
Subject AXS-05 Unknown — —
Comparator Bupropion Small molecule 105 mg —

Indications

major depressive disorder